Bloomberg Intelligence cover image

Merck to Acquire Terns Pharmaceuticals in $6.7 Billion Deal

Bloomberg Intelligence

00:00

Why Merck Is Aggressive on M&A

Discussion of Keytruda's patent cliff and CEO Rob Davis's stated appetite for multibillion-dollar deals.

Play episode from 03:12
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app